Amarin Corp Plc (AMRN)

[Nukemtiltheyglow]

Hey Raf; the study/PR put out @ 7:00 am today.... its different than the diabetes In Vitro study from last week.
New In Vitro Eicosapentaenoic Acid Study Data to Be Presented at the National Lipid Association Scientific Sessions in Chicago

Jun 11, 2015 07:00:00 (ET)


New In Vitro Eicosapentaenoic Acid Study Data to Be Presented at the National Lipid Association Scientific Sessions in Chicago

BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 11, 2015) - Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at the National Lipid Association Scientific Sessions being held June 11-14 in Chicago. The study of the inhibitory effect of eicosapentaenoic acid (EPA) on the formation of cholesterol crystalline domains in model biological membranes subjected to high cholesterol levels (to simulate atherosclerotic-like conditions) indicated a level of reduction with EPA that was not reproduced with other triglyceride-lowering agents tested. The poster, titled "Eicosapentaenoic Acid (EPA), But Not Other TG-Lowering Agents, Reduces Cholesterol Domain Levels in Atherosclerotic-Like Model Membranes," will be presented at the author Q&A session scheduled for June 13, 2015 from 11:20 a.m.-12:20 p.m. CDT.

"This study was conducted in vitro using model biological membranes under conditions of hypercholesterolemia," commented Preston Mason, Ph.D., of Brigham and Women's Hospital and the study's lead investigator. "The purpose of the study was to examine whether EPA, under atherosclerotic-like conditions, can reduce the formation of cholesterol crystalline domains. Our research team found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65% (p<0.05) as compared to vehicle-treated (ethanol) controls."

Additional studies are needed to determine if the effects of EPA shown in this study would have clinically meaningful benefit in the human body.

This poster will be presented by Dr. R. Preston Mason, PhD, of Brigham and Women's Hospital. Dr. Mason is also the President and Founder of Elucida Research.